TotalMarketCap

Recursion Pharmaceuticals

RXRXNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$2.183 B

$3.51 -9.66%

Close of 6 Nov 2026

As of 6 Nov 2026, Recursion Pharmaceuticals (RXRX) has a market capitalization of $2.18B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$74.7M

#2585 by revenue

Earnings

-$644.8M

Loss-making

Shares outstanding

622,759,259

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #30Beam TherapeuticsBEAM$2.68B
  2. #31VericelVCEL$2.65B
  3. #32Recursion PharmaceuticalsRXRX$2.18B
  4. #33Hemab TherapeuticsCOAG$2.13B
  5. #34Biocryst PharmaceuticalsBCRX$1.95B

What if Recursion Pharmaceuticals were worth as much as…

Open the what-if tool →

Gold $28.2T

$45,341.56

Per share 12,936× higher

Bitcoin $1.53T

$2,453.35

Per share 700× higher

Apple $5.02T

$8,054.13

Per share 2,298× higher

Or at a round number

$5.00B$10.0B$20.0B$50.0B

Where these numbers come from

Share counts and financials for Recursion Pharmaceuticals are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.